Nonadherence in inflammatory bowel disease:: Results of factor analysis

被引:117
|
作者
Cerveny, Petr
Bortlik, Martin
Kubena, Ales
Vlcek, Jiri
Lakatos, Peter Laszlo
Lukas, Milan
机构
[1] Charles Univ Prague, Fac Phar Hradec Kralove, Dept Social & Clin Pharm, Prague 50005, Czech Republic
[2] Charles Univ Prague, Gastroenterol Ctr, Inflammatory Bowel Dis Unit, Dept Med 4, Prague, Czech Republic
[3] Semmelweis Univ, Dept Med 1, Budapest, Hungary
关键词
Crohn's disease; mesalamine; patient compliance; ulcerative colitis;
D O I
10.1002/ibd.20189
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The purpose of the study was to assess overall nonadherence to treatment among patients with Crohn's disease (CD) and ulcerative colitis (UC) in a single tertiary center. Methods: A total of 177 patients were enrolled in this study (84 males, 93 females; 117 CD, 60 UC). Patients were interviewed about their nonadherent behavior and their answers were analyzed using factor analysis. Urine samples were collected from a subcohort of 47 patients treated by mesalamine to verify the presence of 5-ASA or its metabolites. Results: Overall intentional nonadherence was reported by 38.9% of patients; 18.6% of the patients discontinued the treatment at least once. Intentional dose reduction was reported by 18% of patients; 14.7% of patients occasionally did not refill their medications on time. There were no differences in adherence between males and females, disease type, previous bowel surgery, or marital, smoking, and nonsmoking status. More than 38% of patients reported unintentional nonadherence. Factor analysis proved that nonadherence increased with a higher education level of the patients and decreased with older age. Adverse drug effects strongly contributed to nonadherence. Nonadherent patients were more likely to be chronically active or in relapse (tau = 0.212; P = 0.002). In the group of 47 patients whose urine was analyzed, 6 cases (12.7%) were negative for mesalamine or its metabolite. Conclusions: The overall intentional nonadherence with medical therapy is relatively high among IBD patients and should be taken into account when a patient's response to treatment is unsatisfactory. Therefore, problems of nonadherence should be discussed with all IBD patients.
引用
收藏
页码:1244 / 1249
页数:6
相关论文
共 50 条
  • [21] Tumour necrosis factor and inflammatory bowel disease
    Densem, CG
    [J]. BRITISH JOURNAL OF SURGERY, 1998, 85 (01) : 138 - 138
  • [22] Tumour necrosis factor and inflammatory bowel disease
    Armstrong, AM
    Gardiner, KR
    Kirk, SJ
    Halliday, MI
    Rowlands, BJ
    [J]. BRITISH JOURNAL OF SURGERY, 1997, 84 (08) : 1051 - 1058
  • [23] Is nutrition an aetiological factor for inflammatory bowel disease?
    Cashman, KD
    Shanahan, F
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (06) : 607 - 613
  • [24] Activated Factor XI and Tissue Factor in Inflammatory Bowel Disease
    Undas, A.
    Owczarek, D.
    Gissel, M.
    Salapa, K.
    Mann, K. G.
    Butenas, S.
    [J]. INFLAMMATORY BOWEL DISEASES, 2010, 16 (09) : 1447 - 1448
  • [25] Osteonecrosis in Inflammatory Bowel Disease: Clinical Features, Risk Factor Analysis, and Outcomes
    Bakhshi, Zeinab
    Yadav, Siddhant
    Harmsen, W. Scott
    Varayil, Jithinraj Edakkanambeth
    Karls, Kevin A.
    Tremaine, William J.
    Loftus, Edward V., Jr.
    [J]. INFLAMMATORY BOWEL DISEASES, 2023, 29 (08) : 1223 - 1230
  • [26] Factor analysis of the stigma scale-child in pediatric inflammatory bowel disease
    Gamwell, Kaitlyn L.
    Roberts, Caroline M.
    Kraft, Jacob D.
    Edwards, Clayton S.
    Baudino, Marissa N.
    Grunow, John E.
    Jacobs, Noel J.
    Tung, Jeanne
    Mullins, Larry L.
    Chaney, John M.
    [J]. JOURNAL OF PSYCHOSOMATIC RESEARCH, 2023, 164
  • [27] Dyadic Confirmatory Factor Analysis of the Inflammatory Bowel Disease Family Responsibility Questionnaire
    Greenley, Rachel Neff
    Reed-Knight, Bonney
    Blount, Ronald L.
    Wilson, Helen W.
    [J]. JOURNAL OF PEDIATRIC PSYCHOLOGY, 2013, 38 (08) : 871 - 882
  • [28] Nonadherence to anti-TNF therapy predicts clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study
    van der Have, M.
    Oldenburg, B.
    Kaptein, A. A.
    Jansen, J. M.
    Scheffer, R. C.
    van Tuyl, S. A.
    van der Meulen-de Jong, A. E.
    Pierik, M.
    Siersema, P. D.
    van Oijen, M. G.
    Fidder, H. H.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S52 - S53
  • [29] Analysis of the cellular basis of keratinocyte growth factor overexpression in inflammatory bowel disease
    Finch, PW
    Cheng, AL
    [J]. GUT, 1999, 45 (06) : 848 - 855
  • [30] Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort
    Greuter, Thomas
    Porchet, Frederic
    Braga-Neto, Manuel B.
    Rossel, Jean-Benoit
    Biedermann, Luc
    Schreiner, Philipp
    Scharl, Michael
    Schoepfer, Alain M.
    Safroneeva, Ekaterina
    Straumann, Alex
    Rogler, Gerhard
    Vavricka, Stephan R.
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (10) : 1196 - 1207